Ref ID: 19440
Author:
L. Drgona,1 E. Bojtarova,2 B. Ziakova,2 L. Demitrovicova,3
E. Mikuskova,3 I. Oravkinova4 and A. Vranovsky3
Author address:
1National Cancer Institute and Comenius University, Bratislava,
Slovak Republic; 2University Hospital, Bratislava, Slovak Republic;
3National Cancer Institute, Bratislava, Slovak Republic and
4Children’s University Hospital, Kosice, Slovak Republi
Full conference title:
6th Trends in Medical Mycology 2013
Date: 11 October 2014
Abstract:
Objective To assess clinical response and safety of amphotericin B
lipid complex (ABLC) administration in patients with hematologic
malignancy and/or hematopoietic stem cell transplantation, with
invasive fungal infections despite primary antifungal prophylaxis.
Methods Observational, mulicentric, non-interventional study from
3 centers in Slovakia during the years 2010-2012. Patients with
breakthrough IFD while on antifungal prophylaxis who were treated
with ABLC were enrolled. EORTC/MSG criteria 2008 were used for
classification of IFD. Data regarding risk factors, prophylaxis,
response to ABLC, toxicity and survival at the end of the study and
at day + 30 after the last dose of ABLC was collected and analyzed.
Results 47 adult patients (26 males) with hematological malig-
nancy, with average age 47 years, mainly with AML (60%) and ALL
(17%) were enrolled. 5 patients underwent allogeneic HSCT. 36
patients were neutropenic for average 18 days (2-52 days). Prophy-
lactic posaconazole was administred in 25, fluconazole in 13, voriko-
nazole in 8 patients and micafungin in 1 patient. Average duration
of prophylaxis was 23 days (3-120 days). Proven/probable IFD was
documented in 26 patients, possible IFD in 21 cases. The most com-
mon IFD reported was invasive aspergillosis (42 cases/89%). ABLC
was administred in standard dose (3.0-5.2 mg/kg), in 42 patients as
monotherapy, with average duration of 13 days (4-30 days). Com-
plete and partial response (CR+PR) rate at the end of ABLC therapy was 57% (14% + 43%). Survival at this time point was 85%. Sur-
vival at day 30 after the stop of ABLC therapy was 74%, majority of
patients continued with other antifungal treatment (follow-on ther-
apy or secondary prophylaxis in 80%). 14 patients (30%) developed
toxicity (9 cases of nephrotoxicity). Average serum creatinine value
was 71 and 97 (lmol/L) at the start and at the end of ABLC admin-
istration, respectively.
Conclusion Due to our observation, ABLC is reasonable choice for
treatment of breakthrough IFD in high-risk hematological patients
when azole prophylaxis failed. Clinical response and toxicity of ABLC
were acceptable but follow-on antifungal therapy or secondary pro-
phylaxis after polyene discontinuation is usually needed to maintain
the response.
This study was supported by Cephalon/Teva.
Abstract Number: p381
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Mrs Ange Brennan (UK)
2024
n/a
-
v
Tianyu Lianga, Nir Osherovb, Ruoyu Lia, Qiqi Wanga, Wei Chena, Zhe Wana, Wei Liua*
2024
n/a
-
v
Jillian Simard, MD,1 Christopher Melani, MD,2
Rahul Lakhotia, MD,1
Michail S. Lionakis, MD
ScD,*,3
Stefania Pittaluga, MD PhD,4
James D. Phelan, PhD,*,1 Jagan R. Muppidi, MD
PhD,*,1
Lydia L. Chou, CRNP,*,1
Matthias Holdhoff, MD PhD,*,5 Michael Glantz, MD PhD,*,6
John A. Butman, MD PhD,*,7 Andrea Nicole Lucas, RN,*,8
Seth M. Steinberg, PhD,*,9
Elaine
S. Jaffe, MD,4
Louis M. Staudt, MD PhD,1
Wyndham H. Wilson, MD PhD,1 Mark Roschewski, MD102020
n/a
-
v
Mark Roschewski, MD,1
Christopher Melani, MD,2
Rahul Lakhotia, MD,3
Stefania Pittaluga, MD
PhD,4
James D. Phelan, PhD,*,3
Cody Peer, PhD,*,5 Michail S. Lionakis, MD ScD,*,6 Lydia
L. Chou, CRNP,*,3 Matthias Holdhoff, MD PhD,*,7 Michael Glantz, MD PhD,*,8 Jan Drappatz, MD,*,9
Catherine Lai, MD MPH,10 John A. Butman, MD PhD,*,11 Andrea Nicole Lucas, RN,*,12 Seth
M. Steinberg, PhD,*,13 William D. Figg, PhD,*,14 Elaine S. Jaffe, MD,4
S. Percy Ivy, MD,*,15
Richard F. Little, MDMPH,16 Louis M. Staudt, MD PhD,3
Wyndham H. Wilson, MD PhD32020
n/a
-
v
Binav Baral, MD,*,1 Prasanth Lingamaneni,*,2 Trilok Shrivastava, MD,*,3 Maryam Zia,4 Ishaan Vohra, MD,*,2
Krishna Rekha Moturi*,32020
903
n/a
-
v
Maxwell Green1, Scout Treadwell1, Geetha Gowda1, John Carlson, MD, PhD2
2023
610
n/a
-
v
Catherine Blackwood, PhD1 , Angela Lemons, MS2 , Rachael Rush3 , Walter McKinney2 , Dori Germolec4 , Donald Beezhold, PhD2 , Brett Green, PhD5 , Tara Croston, PhD6
2023
583
n/a
-
v
Catherine Blackwood, PhD1 , Angela Lemons, MS2 , Rachael Rush3 , Walter McKinney2 , Dori Germolec4 , Donald Beezhold, PhD2 , Brett Green, PhD5 , Tara Croston, PhD6
2023
583
n/a
-
v
Jennifer Roper, MD1, Sebastian Ochoa, MD2, Anahita
Agharahimi, MSN, CRNP2, Justina Pfister, RN2, Magdalena
Walkiewicz, PhD2, Amanda Urban, DNP, CRNP3, Rajarshi
Ghosh, PhD2, Michail Lionakis, MD, ScD2, Lisa Kohn, MD, PhD4, Kenneth Olivier, MD, MPH2, Alexandra Freeman, MD22023
516
n/a
-
v
Utkucan Acar, Gloria Sheng, Terrie Ahn, Lisa Kohn, Maria Garcia Lloret, Manish Butte
2022
82
n/a